Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study.
Patients with high-risk essential thrombocythemia require cytoreductive therapy in order to normalize the elevated platelet counts. We evaluated the efficacy and toxicity of pegylated interferon in high-risk essential thrombocythemia in a phase II trial. Thirty-six patients with high-risk essential thrombocythemia (median age 54 years; range, 24-72 years) were studied. The dose of pegylated interferon was initially 50 mg per week and could be escalated up to 150 mg per week. During the first three months platelet counts decreased significantly from a median baseline count of 895x10(9)/L (range: 383-1779) to a median count of 485x10(9)/L (range: 211-1283; p<=0.001). A complete response was defined as platelet counts < 450x10(9)/L. The complete response rate was 39%, 47%, 58% and 67% at 3, 6, 9 and 12 months of treatment, respectively. There were 25%, 11%, 8% and 0% poor responders, defined as patients with platelet counts > 600x10(9)/L, at 3, 6, 9 and 12 months of treatment, respectively. After a median time of 23 months (range 3-39 months) 23 of 36 patients (64%) are still receiving pegylated interferon. In ten patients (28%) treatment was stopped due to grade 1 to 2 toxicity, classified according to the WHO standard toxicity scale. One patient, who responded partially to pegylated interferon (platelet count 542x10(9)/L), had a cerebral stroke after 23 months of treatment. In high-risk essential thrombocythemia sustained treatment with pegylated interferon is effective and safe in reducing platelet counts with a toxicity comparable to that of conventional interferon.